Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells

Updated: May 21

SCIENTIFIC REPORTS, A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells in Living Donor Kidney Transplants” April 2018.


Download the full report below.

A Phase I Clinical Trial with Ex Vivo Treg cells in Living Donor Kidney Transplants
.pdf
Download PDF • 3.69MB

 

About TRACT Therapeutics

TRACT Therapeutics, Inc. is a clinical stage biotechnology company developing a novel therapeutic approach to restoring immune balance in organ transplantation and autoimmune disease. Its proprietary platform technology, using autologous polyclonally expanded regulatory Tcells was developed at Northwestern University by pioneer, Joseph R Leventhal, MD, PhD and his research colleagues. TRACT has recently received FDA approval to initiate a Phase 2 trial with Trigs in kidney recipients.


This press release contains forwardlooking statements that express the belief, potential anticipation or expectation, as well as other statements which are not historical fact, and statements related to clinical trials and their results, design, FDA product approvals or other marketing approvals, features, functionality and performance. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward looking statements.

Recent Posts

See All